Platform Changelog

Candidate List Management and Developability Risk Analysis

• Added candidate list management, allowing researchers to consolidate antibody sequences into a single list for comparison, tracking, and follow-up analysis.
• Added five-dimensional developability risk analysis across aggregation, chemical modification, humanness, polyreactivity, and viscosity to help assess potential risks at the sequence level and support candidate selection and optimization.

Upgrades to Antibody Design Workflows

• Added a CDR diversity engineering workflow, supporting sequence- and structure-pattern-based antibody optimization to expand AI-assisted antibody engineering.
• Upgraded the affinity maturation workflow to support configuring key constraint sites for more flexible, targeted optimization.

AI Agent Capability Upgrade

• Added multi-step task planning, enabling the AI to break down R&D goals into tasks, plan workflows, and execute them continuously for more complex antibody design and analysis.

Click.mAb. V3.0 Officially Launched

The new AI antibody R&D collaboration platform is officially launched. The platform is built around project spaces, research goals, and AI Agent interactions, enabling individual researchers and teams to conduct antibody design, analysis, and collaboration through natural language. It provides several core antibody R&D capabilities, including:

• De novo antibody design for target epitopes
• Antibody affinity maturation
• Antibody humanization
• Nanobody humanization
• Epitope prediction
• Lightweight tools for antibody analysis and visualization

Also supports structured management and visualization of computational results, including antibody sequence analysis, structural model display, and design result comparison, helping researchers better understand computational results and advance subsequent research.